NP-252
| Code | Size | Price |
|---|
| TAR-T28191-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28191-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28191-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
NP-252 is a calcium channel antagonist potentially for the treatment of angina pectoris and congestive heart failure.
CAS:
132031-81-3
Formula:
C26H35N3O5
Molecular Weight:
469.582
Purity:
0.98
SMILES:
CCCCCCCCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)NC1CC1
References
1. Hojo M, Tanaka Y, Katayama O, Teramoto N. Acute antihypertensive effects of the new generation calcium antagonist 3-pyridine carboxylic acid 5-[(cyclopropylamino)-carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitrophen yl) octyl ester on conscious spontaneously hypertensive rats and renal hypertensive rats. Arzneimittelforschung. 1993 Aug;43(8):847-51. PubMed PMID: 8216440.
2. Hojo M, Teramoto N, Hata H, Katayama O, Tatsumi H, Shibata S. Cardiovascular effects of the new generation calcium antagonist 3-pyridine carboxylic acid 5-[(cyclopropylamino)carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitropheny l) octyl ester. Arzneimittelforschung. 1992 May;42(5):621-8. PubMed PMID: 1530674.
3. Shibata S, Satake N, Kodama I, Hester RK, Wang CG, Jino H, Hojo M, Tatsumi H, Gandhi V, Jones DJ. Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol. 1991 Oct 22;203(3):337-44. PubMed PMID: 1773820.
4. Akimoto Y, Kurahashi K, Usui H, Fujiwara M. Vasoinhibitory effect of NP-252, a new dihydropyridine derivative, in canine cerebral artery. Life Sci. 1991;48(2):183-8. PubMed PMID: 1994178.